AIHTA - Announcements

©stock.adobe.com

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you three new Fact Sheets.

Fact Sheet No. 130 (May 2023)
Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Fact Sheet No. 131 (May 2023)
Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)

Fact Sheet No. 132 (May 2023)
Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma

More...

©stock.adobe.com

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you one new Fact Sheets.

Fact Sheet No. 129 (April 2023)
Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

More...

©AIHTA

Sponsoring of patient initiatives in Austria.5th Update of the Systematic Analyses 2014 to 2019

As patient initiatives expand their activities and continue to professionalise, their need for financial resources, which often gets bankrolled by pharma-ceutical companies, increases accordingly. To make these financial transactions more transparent, the pharmaceutical industry responded with volun-tary disclosure commitments. AIHTA (then still as LBI-HTA) systematical-ly analysed the content of these voluntary disclosures of sponsorship for pa-tient initiatives by members of the Association of Austria’s Pharmaceutical Industry (PHARMIG - Verband der pharmazeutischen Industrie Österreichs) for the first time in 2014 and aims to carry out regular and consistent moni-toring of these payments. The present fifth update systematically researched the extent of financial support to patient initiatives disclosed by member companies of PHARMIG for the fiscal year of 2021.

Publication: Policy Brief No. 007/5. Update: https://eprints.aihta.at/1443/
Contakt: Claudia Wild

More...

©stock.adobe.com

Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements

Preexposure prophylaxis (PrEP) is an antiretroviral therapy-based HIV prevention strategy to prevent HIV infection in people who have not been infected with the virus but are at high risk of infection. The report aimed to provide an update evidence synthesis based on a systematic literature search regarding the effectiveness and safety of in the EU and/ or US approved oral and parenteral PrEP pharmaceutical to prevent HIV infection in populations at risk. Additionally, the report addressed organisational, economic, patient/social, ethical and legal aspects to support evidence-based decision-making process on PrEP in Austria.

Publication: HTA Project Report No. 152: https://eprints.aihta.at/1436/
Contact: Inanna Reinsperger

More...

©stock.adobe.com

Update PET/PET-CT evidence for need based planning in the area of oncology

This report is based on that of the LBI-HTA of 2015 and the updates of 2018 and 2020. Various guideline databases and policies were searched to identify the recommended oncological indications for the use of PET/PET-CT applications. In addition to guideline databases, recommendations and non-recommendations from professional societies were considered.

The guideline search identified a total of 122 recommendations regarding the use of PET. The majority of the recommendations (n=112) resulted from the guideline search and database search of national professional societies. The search in supranational professional societies resulted in 10 recommendations. A further 36 recommendations were directed against the use of PET ("inappropriate" cancer indications).

The overall recommendations of the present 2023 update (as in the previous year's 2015 & 2018 reports, as well as the 2020 update) indicate little benefit from PET as a primary or standard diagnostic (not least because of radiation exposure). The summarised evidence from guidelines can be used as a guideline for investment decisions.

Publication: Policy Brief No. 003/3. Update: https://eprints.aihta.at/1442/
Contact: Claudia Wild

More...

©stock.adobe.com

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you four new Fact Sheets.

Fact Sheet No. 125 (April 2023)
Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet No. 126 (April 2023)
Ivosidenib (Tibsovo®, Tidhesco®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet No. 127 (April 2023)
Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma

Fact Sheet No. 128 (April 2023)
Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

More...

©AIHTA

Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol

Up to 20% of women and 10% of men experience a mental illness during pregnancy and in the first year after birth. Due to the potentially severe effects on parents and child, there is an urgent need for rapid and effective care. This report provides a mapping of current care structures in Austria. The report is part of the FWF-funded research project "Co-designing perinatal mental health care in Tyrol". The report is to seen in connection with another report which has recently been published as part of the project and which describes the international recommendations on perinatal and infant mental health care (https://eprints.aihta.at/1420/1/HTA-Projektbericht_Nr.148.pdf).

Publication: HTA Projektbericht No. 151: https://eprints.aihta.at/1437/
Contact: Ingrid Zechmeister-Koss

More...